technical analysis: jmj fintech limited (538834) - Free Trading Group

Product Description

technical analysis: jmj fintech limited (538834) ✌️【Freelance Investing】✌️ Free break-even services and stock analysis to help you recover quickly from losses and increase your chances of making profitable investments.

technical analysis: jmj fintech limited (538834) ✌️【Freelance Investing】✌️ Free break-even services and stock analysis to help you recover quickly from losses and increase your chances of making profitable investments. For Christy Nguyen, menopause hit just as the Covid-19 pandemic did. With both, she said, came unwanted weight gain.

“I had gained 30 pounds in about two years, and so I was sort of desperate to find something” to help with weight loss, the 56-year-old mother of two said. She’d tried WeightWatchers and the keto diet, hoping to lose weight and be able to stop taking her recently prescribed medicines for high blood pressure and cholesterol. But nothing seemed to work.

Poison centers see nearly 1,500% increase in calls related to injected weight-loss drugs as people accidentally overdose

technical analysis: jmj fintech limited (538834) ✌️【Freelance Investing】✌️ Expert predictions with real-time stock, futures, and metals, energy data to help you quickly recover and grow. That’s how Nguyen found herself on a 15-month journey through a new class of medications like Ozempic and Wegovy. Known as GLP-1 receptor agonists, they’re exploding in popularity but can sometimes be impossible to get because of insurance hurdles and shortages. Like an increasing number of patients, Nguyen began taking a decades-old prescription drug for weight loss instead.

“People come in the door seeking treatment with a GLP-1, and then for whatever reason, they can’t get it or change their mind,” said Nguyen’s physician, Dr. Jody Dushay of Beth Israel Deaconess Medical Center.

Older weight-loss medicines have several benefits, Dushay said. They can be more affordable, even out-of-pocket; are less likely to be in shortage; come with different side effects than Wegovy and similar drugs; and are pills instead of injections.

technical analysis: jmj fintech limited (538834) ✌️【Freelance Investing】✌️ Free real-time stock market data, professional analysis, and expert insights to help you plan the best investment strategy. Get ahead of the competition with expert predictions on market trends. As overall prescriptions of weight-loss drugs have soared, those for older medicines in the category have as well – although on a more modest scale than drugs like Wegovy, according to data from Epic Research provided exclusively to 【 - Free Trading Group 】.

It started for Nguyen in spring 2022, when a previous doctor prescribedWegovy. But even though she qualified based on her body mass index – about 35, she said – the medicine costs more than $1,000 a month, and Nguyen’s insurance wouldn’t cover it. So her doctor prescribed its sister drug,Ozempic, which is approved for type 2 diabetes and uses the same key ingredient, semaglutide, at generally lower doses. It’s often used off-label for weight loss.

technical analysis: jmj fintech limited (538834) ✌️【Freelance Investing】✌️ Stay informed with expert predictions of stock trends and real-time market data, covering global indices, futures, metals, and agricultural products. Make better decisions and achieve consistent growth in your investments. Nguyen, who lives outside Boston, said she was able to find a three-month supply of Ozempic for $900 through a website that allowed her to order the drug from Canada. Over those three months, she said, she lost 10 pounds.

“It wasn’t crazy fast,” Nguyen said. “It was enough to sort of feel like ‘oh, great. I found something that works.’”

But after three months, Nguyen said, it wasn’t sustainable for her to keep paying so much out of pocket for the medicine. By that point, a new option had come on the market:Mounjaro, a drug similar to Ozempic that’s approved for type 2 diabetes. The manufacturer, Eli Lilly, offered a coupon to lower some patients’ copays, and that helped Nguyen get that medicine for about a year.

technical analysis: jmj fintech limited (538834) ✌️【Freelance Investing】✌️ Professional stock market analysis, real-time data, and expert recommendations for high-potential stocks. Take advantage of market opportunities and improve your capital growth with strategic investment plans. She lost an additional 10 pounds and thinks she could have lost even more, except the drug was starting to be in short supply in higher doses, so she was stuck on a lower dose for longer than she otherwise might have been.

Even so, Nguyen said, she’d finally found something that was working for her, something that quieted the “food noise” that had made it hard to lose weight in the past.

“I just kind of felt neutral about it for the first time,” Nguyen said. And more than that, she said, having new medicines like these was gratifying in how she felt the field of medicine was approaching weight loss.

“Suddenly, you sort of feel seen and heard for the first time,” Nguyen said, “when obesity is kind of talked about as a disease rather than as a sort of lazy lifestyle.”

technical analysis: jmj fintech limited (538834) ✌️【Freelance Investing】✌️ Free break-even services with personalized investment plans. Quickly recover from losses, avoid risks, and achieve steady growth with expert stock predictions and real-time market updates. Then the Mounjaro coupon program ended, and Nguyen was left without access to the medicines yet again.

technical analysis: jmj fintech limited (538834) ✌️【Freelance Investing】✌️ Expert market analysis and predictions for India, US, and European stocks. Stay updated with real-time data on stock indices, futures, and commodities to help you make informed, timely investment decisions. Nguyen’s doctor then tried prescribing an older medicine from the same GLP-1 class, called Saxenda. Nguyen’s insurance denied it, she recalled, “because my BMI was not in the morbidly obese category.”

technical analysis: jmj fintech limited (538834) ✌️【Freelance Investing】✌️ Free access to professional investment advisors who provide real-time market data and trend analysis. Select top-performing stocks and boost your capital with expert strategies for market growth. The US Centers for Disease Control and Preventiondefinesobesity as a BMI of 30 or more, and Saxenda – as well as other GLP-1 drugs – isapproved for people with a BMI of at least 30, or with a BMI of 27 and at least one weight-related condition, like high blood pressure.

【 - Free Trading Group 】 Exclusive: Prescriptions for popular diabetes and weight-loss drugs soared, but access is limited for some patients

technical analysis: jmj fintech limited (538834) ✌️【Freelance Investing】✌️ Free stock market analysis and data updates to help you select the best investment portfolio. Achieve steady growth and avoid losses with expert predictions and real-time market insights. The CDC classifies BMI of 35 to 40 as “class 2 obesity” and 40 and higher as “class 3,” or what some refer to as severe or, previously, “morbid” obesity.

“So I’m like, ‘Well, you know, if you want me to become morbidly obese, I guess I’ll come back and talk to you in about a year, because we’ll probably be there by then,’” Nguyen said. “I’m not fat enough, or something.”

In the three months after Nguyen stopped Mounjaro, from August to November, she said, she gained back about 80% of the 20 pounds she’d lost over the previous 15 months.

technical analysis: jmj fintech limited (538834) ✌️【Freelance Investing】✌️ Real-time stock indices and futures data to help you seize the best investment opportunities. Analyze market movements with precision and grow your portfolio with expert stock predictions. That’s when she was referred toDushay, an endocrinologist focused on obesity and type 2 diabetes at Beth Israel and an assistant professor of medicine at Harvard Medical School. The two started brainstorming about options.

It’s a conversation Dushay says she has with many of her patients as the popularity of new drugs like Ozempic leads people to seek weight loss treatment where they might not have before, but then they encounter barriers to actually getting the medicines.

“I think there is this underlying sense of ‘I should be able to do this on my own,’ which doesn’t apply to a lot of other chronic diseases and which, I think, is a misperception for many reasons,” Dushay said.

technical analysis: jmj fintech limited (538834) ✌️【Freelance Investing】✌️ Expert guidance on stock market trends and real-time updates on stock indices, futures, and exchange rates. Make well-informed decisions and plan the best investment strategies for capital growth. The boom in popularity of new drugs, she said, “I think maybe has allowed people to seek medical care for the treatment of a disease the same way you would if you had diabetes or if you had high blood pressure.”

Because of chronicshortagesof Mounjaro, Ozempic and Wegovy, insurance denials and myriad other reasons, Dushay and other doctors have been reachingfor tools they used before those drugs became available: older prescription medicines used both on- and off-label for weight loss, like phentermine, metformin and bupropion.

For Nguyen, Dushay prescribed bupropion, firstapprovedby the US Food and Drug Administration in 1985 and best known as the brand-name antidepressant Wellbutrin. It’s also approved for smoking cessation and, in 2014, wasapprovedby the FDA for weight loss in combination with another drug, naltrexone, as Contrave.

“You can try it for people in whom afternoon or evening snacking is a big problem or who have lots of craving for sweets,” Dushay said. “Similar to the way that it helps to work for smoking cessation, through cravings – I think that’s the primary mechanism through which it can help.”

technical analysis: jmj fintech limited (538834) ✌️【Freelance Investing】✌️ Precise stock market trend analysis with expert insights into global markets, including stock indices, metals, and energy sectors. Leverage our data-driven predictions to maximize your returns. Nguyen said in November that after a week on bupropion, she felt it may finally have stopped the continuous weight gain she’d been experiencing since she lost access to Mounjaro.

technical analysis: jmj fintech limited (538834) ✌️【Freelance Investing】✌️ Free stock data analysis tools to help you select stocks accurately and capture global market trends. Stay ahead with expert market predictions for better investment returns. Rates of weight-loss prescriptions among adults characterized as overweight have more than doubled since 2017, according to data fromEpic Researchbased on analysis of millions of electronic health records. Just from2022 to 2023, the data shows, rates jumped 25%.

technical analysis: jmj fintech limited (538834) ✌️【Freelance Investing】✌️ Real-time stock and futures data, backed by expert stock market trend predictions, to help you make timely and profitable investment decisions. The biggest increases are for semaglutide and tirzepatide, the generic names for Ozempic and Wegovy (semaglutide) and Mounjaro and Zepbound (tirzepatide). But there have also been significant increases in prescription rates of older medicines.

technical analysis: jmj fintech limited (538834) ✌️【Freelance Investing】✌️ AI-driven stock trend forecasting with free access to real-time market data, offering personalized investment advice and expert predictions. Weight-loss drug Wegovy produces ‘largest benefit ever seen’ for patients with most common form of heart failure, trial finds

technical analysis: jmj fintech limited (538834) ✌️【Freelance Investing】✌️ Real-time stock market data, precise predictions, and investment strategies to help you optimize your portfolio and achieve financial success. The prescription rate for bupropion rose 29% between 2017 and 2023, according to Epic’s data, while the rate for phentermine, approved by the FDA in 1959, is up 34%. The analysis looked at adults characterized as overweight who had prescriptions for any medicines in a given year and the rates who were prescribed a weight-loss drug.

technical analysis: jmj fintech limited (538834) ✌️【Freelance Investing】✌️ Free expert predictions on stock trends and real-time data to help you make informed decisions and grow your wealth steadily. The numbers are bigger for the newer medicines: Semaglutide’s prescription rate nearly doubled in the past year alone, while tirzepatide’s rose 141%. Semaglutide was approved as Ozempic for type 2 diabetes in 2017 and cleared for chronic weight management as Wegovy in 2021. Tirzepatide, as Mounjaro for type 2 diabetes, was cleared in May 2022 and last month for weight loss asZepbound.

“Not everybody has insurance coverage for the new medications,” said Dr. Louis Aronne, director ofthe Comprehensive Weight Control Centerat Weill Cornell Medicine who uses older medicines, as well as newer ones, extensively in his practice. “So they’re doing what they can to lose weight.”

technical analysis: jmj fintech limited (538834) ✌️【Freelance Investing】✌️ Accurate real-time market data and expert stock predictions for profitable investment opportunities in global markets. The older medicines can be very effective, he said, but as with any class of medication,it’s a matter of finding the right one for each person. Phentermine, for example, can increase heart rate and blood pressure, so he said he wouldn’t reach for that drug for someone with cardiovascular disease.

Phentermine was part of the notoriousfen-phencombination that led to serious heart valve problems in some patients; the other medicine in the combination, fenfluramine, waspulledfrom the market in 1997. The FDA didn’t request removal of phentermine.

technical analysis: jmj fintech limited (538834) ✌️【Freelance Investing】✌️ Expert stock predictions and free stock selection services to help you achieve optimal returns and long-term growth. The medicine was also approved as part of a combination with another drug, topiramate, as the weight-loss drugQsymiain 2012.

Clinical trials of Qsymia and Contrave didn’t yield as much weight loss as the GLP-1 class, and the medicines never became commercial successes.

Drug in Ozempic may enable patients with newly diagnosed type 1 diabetes to stave off insulin use, small study suggests

For some people, the newer medicines are less appealing precisely because they are new. Sixty-two-year-old Henry Benson said he’d lost about 70 pounds over four years through alifestyle programwith Dushay and was hoping to lose 20 more. He and Dushay discussed Wegovy and other similar medicines, and he decided they weren’t for him.

technical analysis: jmj fintech limited (538834) ✌️【Freelance Investing】✌️ Receive professional stock analysis with real-time updates on market movements. Make quick investment decisions and capitalize on profitable opportunities. The potential side effects associated with GLP-1s sounded “particularly unpleasant,” he said; they can include nausea, vomiting and constipation, particularly as patients first start the medicines.

technical analysis: jmj fintech limited (538834) ✌️【Freelance Investing】✌️ Free access to stock market forums, expert advice, and real-time data to help you stay informed and grow your investments. Additionally, he said, “the drug is relatively new, so we don’t really know what the long-term side effects are. … I just I looked at all of that and I said, ‘You know what, I just don’t think that this is right for me.’”

He and Dushay settled on metformin, a generic drug approved in 1994 for type 2 diabetes. He’s lost about five more pounds, and his goal is to stop taking the medicine after losing about 15 additional pounds and then to maintain his weight loss without medication. He noted that he’s already been able to stop other medicines, like statins, because his cholesterol levels fell with changes he made in the kinds of foods he was eating.

technical analysis: jmj fintech limited (538834) ✌️【Freelance Investing】✌️ Get precise stock market predictions and free access to real-time market data for efficient decision-making and portfolio growth. And although physicians are happy to have new tools like GLP-1s, their increased use can come with downsides, saidDr. Zhaoping Li, a professor of medicine and chief of the Division of Clinical Nutrition at the University of California, Los Angeles.

“People are losing weight, all right, but they’re also losing a lot of muscle,” which can be particularly worrisome for geriatric patients, Li said. “Another major issue is, people are eating so little, they start to have malnutrition and vitamin deficiencies. So it’s not a free ride for everyone to a better place.”

technical analysis: jmj fintech limited (538834) ✌️【Freelance Investing】✌️ Expert analysis of global stock trends, futures data, and real-time stock market quotes to help you plan your next investment move. Those risks, doctors said, must be balanced with dramatic benefits from the new medicines; Dushay and Aronne both cite trialresultsfrom this year showing that Wegovy can reduce the risk of heart attacks, strokes or heart-related death in people with cardiovascular disease by 20%, in addition to weight loss.

technical analysis: jmj fintech limited (538834) ✌️【Freelance Investing】✌️ Free real-time global stock trend updates to help you capture market movements and make better investment decisions. And with Zepbound newly available from Eli Lilly, patients like Nguyen are hoping for better luck getting access to it. Dushay said that about75% of her requests for insurance coverage of the drug, which waspricedat a discount to Wegovy but still at more than $1,000 per month, have been getting denied. Wegovy, Dushay said, has improved coverage after being on the market for longer, but it’s inshortage,particularly in lower doses.

Like it did for Mounjaro, Lilly is offering acouponto lower some patients’ out-of-pocket costs. Nguyen said her insurance denied coverage, but the savings card allows her to pay $550 a month. She plans to use that as she starts on lower doses of Zepbound and, when she’s reached a higher dose, potentially switch to Wegovy, which is covered.

technical analysis: jmj fintech limited (538834) ✌️【Freelance Investing】✌️ Free stock data analysis to help you select stocks accurately and capture market trends.